Zebrafish High-Throughput Drug Screening Service

BioVenic provides professional zebrafish high-throughput drug screening (ZHTS) services for innovative drug research, supporting full-process phenotypic screening, efficacy verification and toxicity analysis of small-molecule compounds and drug candidates. Modern preclinical drug discovery is restricted by low screening efficiency and insufficient in vitro-in vivo translational accuracy, while conventional cell and mammalian models have distinct technical drawbacks. With high genetic conservation and complete organ systems, zebrafish serves as a reliable whole-vertebrate model to generate high-quality in vivo preclinical data via genetic modification and high-content imaging technologies.

Ideal Projects We Support

• Novel Small-Molecule Compound Screening: High-throughput phenotypic screening of synthetic small molecules, natural active compounds and compound libraries, efficiently capturing lead compounds with specific therapeutic phenotypes for refractory diseases.
• Candidate Drug Efficacy Secondary Verification: Conduct in vivo functional verification of preliminarily screened active drugs, verify phenotypic activity stability, and screen high-translational preclinical candidates for subsequent experimental research.
• Drug Multi-Organ Toxicity Exploration: Early preclinical safety evaluation of candidate drugs, focusing on developmental toxicity, cardiotoxicity and neurotoxicity phenotype identification to realize early de-risking of drug candidates.

Fig 1. Workflow of screening the number of hematopoietic stem cells in the tail of zebrafish embryos. ¹

Common Challenges We Help Address

• Mass compound batch screening is prone to cross-contamination and uneven compound exposure, leading to unstable phenotypic results and false positive or false negative screening outcomes.
• Subtle drug therapeutic phenotypes and mild toxic damage are difficult to be accurately distinguished from normal embryonic developmental differences via manual observation and traditional statistical methods.
• Complex disease model phenotypes have low batch repeatability, easily interfering with accurate identification of true active drug candidates in high-throughput screening.
• Traditional screening modes cannot synchronously quantify drug efficacy and multi-organ toxicity, resulting in incomplete preclinical evaluation data of candidate compounds.
• Mass imaging data generated by high-content screening relies on manual analysis, which is time-consuming and prone to subjective statistical errors.

Zebrafish High-Throughput Drug Screening Service

• Targeted Disease Modeling

Applicable Scenarios: Suitable for preclinical modeling of genetic diseases, tumor disorders and multiple organic lesions, supporting customized disease model construction for diverse innovative drug research and phenotypic screening demands.

Technical Capabilities: Adopt precise gene editing technologies to build stable zebrafish disease models, optimizing quantifiable phenotypic indicators matching specific drug therapeutic characteristics.

Deliverables: Standardized disease model phenotypic data, model stability verification results and customized modeling reports for subsequent compound screening and drug efficacy evaluation.

• High-Throughput Drug Screening (HTS)

Applicable Scenarios: Applied to large-batch preliminary screening of small-molecule compound libraries and natural active substances, for early mining of potential lead compounds with therapeutic biological activity.

Technical Capabilities: Utilize automated liquid handling systems for precise gradient compound dosing, combined with high-content imaging to capture real-time drug-induced phenotypic changes in zebrafish larvae.

Deliverables: Batch imaging datasets, compound activity screening statistics, hit compound screening lists and standardized high-throughput screening analysis reports.

• Drug Toxicity Screening & Efficacy Verification

Applicable Scenarios: Used for synchronous verification of therapeutic efficacy and biosafety of candidate drugs, focusing on early identification of developmental, cardiac and neurotoxic risks in preclinical research.

Technical Capabilities: Realize in vivo dual evaluation of drug efficacy and multi-organ toxicity in single zebrafish individuals, assisted by AI quantitative analysis to improve screening accuracy and stability.

Deliverables: Drug efficacy quantitative data, multi-organ toxicity phenotypic records, compound risk assessment results and preclinical dual evaluation reports.

• Validation and Research on Drug Molecular Mechanisms

Applicable Scenarios: Suitable for secondary verification of screened active drugs and in-depth exploration of their in vivo therapeutic pathways, supporting druggability optimization and mechanism academic research.

Technical Capabilities: Conduct gradient dose-response testing, combined with molecular biological detection to analyze key gene expression and signal pathway changes induced by active compounds.

Deliverables: Dose-effect relationship data, molecular pathway verification results, compound mechanism analysis and detailed preclinical research reports.

Standardized Service Workflow

All zebrafish high-throughput drug screening experiments follow BioVenic's unified internal scientific research specifications to ensure stable, repeatable and high-quality experimental data output.

1. Customized Scheme Design: Combine client drug research objectives to select matching disease models, formulate compound concentration gradients and determine core phenotypic detection indicators.
2. Standard Model Construction & Grouping: Complete gene editing modeling or tumor xenograft construction, screen developmentally unified zebrafish larvae and set up multiple control groups.
3. Automated Compound Exposure: Use robotic equipment for precise multi-well compound dosing and continuous standardized larval culture.
4. High-Content Phenotypic Imaging: Conduct batch microscopic imaging to collect drug efficacy and organ toxicity phenotypic data at fixed time points.
5. AI-Assisted Data Analysis: Complete quantitative statistics of phenotypic indicators, screen active lead compounds and summarize drug toxicity characteristics.
6. Secondary Verification & Mechanism Exploration: Verify screened active compounds and explore their in vivo molecular action mechanisms.
7. Academic Report Delivery: Integrate all experimental data and analysis conclusions to deliver standardized scientific research reports.

Fig 2. Workflow of zebrafish high-throughput drug screening (BioVenic Original)

Why Choose BioVenic

• Professional Drug Research Team: The core team has rich experience in preclinical drug screening and zebrafish disease modeling, proficient in phenotypic data quantification and drug molecular mechanism interpretation.
• Customized Screening Solutions: Flexible adjustment of model types, screening indicators and experimental parameters according to different drug attributes and research directions to meet personalized scientific research demands.
• Complete Research Pipeline: Integrates model construction, high-throughput screening, compound verification and mechanism research to provide one-stop preclinical drug screening research services.

Core Application Scenarios

• Early Lead Compound Mining

Rapidly screen active compounds from large-scale compound libraries, efficiently capture potential therapeutic candidates and eliminate invalid compounds at an early stage.

• Lead Compound Optimization

Verify the efficacy stability and safety of modified compounds, optimize drug dosage and administration conditions to improve compound druggability.

• Preclinical Toxicity Early Warning

Realize early identification of multi-organ toxicity of candidate drugs, providing phenotypic basis for drug structural optimization and risk control.

• Drug Mechanism Academic Research

Provide reliable in vivo phenotypic data for exploring drug therapeutic pathways, supporting academic paper publication and research project output.

Frequently Asked Questions

1. What types of drugs are suitable for zebrafish high-throughput screening?
   It is applicable for high-throughput screening and verification of small-molecule compounds, natural active drugs and anti-tumor candidate drugs, covering multiple therapeutic fields such as neurology, cardiology and hematology.
2. What core advantages does zebrafish HTS have over cell screening?
   Different from single-cell detection, zebrafish whole-organism models can synchronously reflect drug in vivo therapeutic efficacy and multi-organ systemic toxicity, with higher physiological authenticity and preclinical translational value.
3. How to avoid false positive results in high-throughput compound screening?
   We set multiple blank and model control groups, adopt gradient concentration screening and secondary phenotypic verification, combined with AI quantitative analysis to effectively eliminate false positive and false negative interference.
4. Is high-throughput batch screening data stable and repeatable?
   We adopt unified embryonic screening standards and automated experimental operation, with multi-group parallel repeated experiments to eliminate individual differences and ensure stable and repeatable batch screening data.

Partner with BioVenic

BioVenic specializes in efficient Zebrafish High-Throughput Drug Screening Service, designed to fast-track early-stage compound screening and drug candidate identification. We know that rapid, large-scale sample screening is key to shortening drug research cycles and lowering experimental costs. Equipped with advanced screening platforms and standardized operating procedures, our expert team delivers high-precision screening results to match your drug discovery goals. For tailored screening solutions, detailed technical specifications, or a competitive project quotation, please contact us. Our professional team is dedicated to supporting your efficient and high-quality drug development progress.

Our products and services are for research use only and cannot be used for any clinical purposes.

Related Services